ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1278

Does Co-existing Systemic Lupus Erythematosus Affect Outcomes of Hospitalizations for Ischemic Stroke?

Ehizogie Edigin1, Precious Eseaton2, Pius Ojemolon3 and Augustine Manadan4, 1John H Stroger Jr. Hospital of Cook County, Chicago, IL, 2University of Benin Teaching Hospital, Benin, 3St. George's University, St. George's, Grenada, 4Cook County Hospital/Rush University Medical center, Chicago, IL

Meeting: ACR Convergence 2020

Keywords: Stroke, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Various studies have shown that individuals with Systemic Lupus Erythematosus (SLE) have a higher risk of stroke and cerebrovascular events than the general population. These events represent a significant cause of death in SLE patients. It is however unclear if SLE patients who develop cerebrovascular events have different outcomes compared to stroke patients without SLE. The aim of this study is to compare the outcomes of patients primarily admitted for ischemic stroke with and without a secondary diagnosis of SLE.

Methods: Data were abstracted from the National Inpatient Sample (NIS) 2016 and 2017 Database. This database is the largest collection of inpatient hospitalization data in the United States (U.S). The NIS was searched for hospitalizations for adult patients with ischemic stroke as principal diagnosis with and without SLE as secondary diagnosis using ICD-10 codes. The primary outcome was inpatient mortality. Hospital length of stay (LOS), total hospital charges, odds of receiving tissue plasminogen activator (TPA), and mechanical thrombectomy were secondary outcomes of interest. Multivariate logistic and linear regression analysis was used accordingly to adjust for confounders. Confounders adjusted for include age, sex, Charleston co-morbidity index, and cardiovascular comorbidities. STATA software was used to analyze the data.

Results: There were over 71 million discharges included in the combined 2016 and 2017 NIS database. Out of 525,570 patients with ischemic stroke, 2,280 (0.43%) had SLE. SLE group was younger (58 vs 70 years, P< 0.0001) and had more females (83% vs 50%, P< 0.0001). The adjusted odds ratio (AOR) for inpatient mortality for ischemic stroke with co-existing SLE compared to without co-existing SLE was 0.95 (95% CI 0.58-1.54, P=0.824). Hospitalizations for ischemic stroke with co-existing SLE had higher mean total hospital charges ($80,306 vs $70,157, P=0.019) and less odds of receiving TPA (OR: 0.61, 95% CI 0.41-0.90, P=0.012) compared to those without co-existing SLE.

Conclusion: Patients admitted primarily for ischemic stroke with a secondary diagnosis of SLE had similar inpatient mortality, more total hospital charges, and less likelihood of receiving TPA compared to those without SLE. LOS and odds of receiving mechanical thrombectomy were similar between both groups. Though SLE is known to increase the risk of cerebrovascular events, SLE does not negatively affect outcomes of patients primarily admitted for ischemic stroke based on this large U.S hospital database.

Table 1: Clinical outcomes of ischemic stroke hospitalizations with and without SLE


Disclosure: E. Edigin, None; P. Eseaton, None; P. Ojemolon, None; A. Manadan, None.

To cite this abstract in AMA style:

Edigin E, Eseaton P, Ojemolon P, Manadan A. Does Co-existing Systemic Lupus Erythematosus Affect Outcomes of Hospitalizations for Ischemic Stroke? [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/does-co-existing-systemic-lupus-erythematosus-affect-outcomes-of-hospitalizations-for-ischemic-stroke/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/does-co-existing-systemic-lupus-erythematosus-affect-outcomes-of-hospitalizations-for-ischemic-stroke/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology